Sep 29, 2025 07:00AM
Sep 29, 2025 07:00AM
May 27, 2025 07:00AM
Jan 21, 2025 07:01AM
Jan 21, 2025 07:00AM
Dec 10, 2024 08:30AM
Nov 21, 2024 06:31AM BioLineRx (BLRX) and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA
Nov 21, 2024 06:30AM
Oct 16, 2024 07:02AM
Oct 16, 2024 07:00AM
Sep 3, 2024 04:10PM
May 30, 2024 07:00AM
May 28, 2024 07:00AM
Apr 17, 2024 07:00AM BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
Mar 26, 2024 07:00AM
Mar 6, 2024 08:00AM
Mar 4, 2024 07:03AM
Mar 4, 2024 07:00AM
Feb 28, 2024 07:00AM
Dec 21, 2023 07:00AM
Nov 20, 2023 07:00AM BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
Oct 31, 2023 09:00AM
Oct 12, 2023 07:00AM
Sep 15, 2023 07:39AM
Sep 11, 2023 07:00AM
Sep 11, 2023 07:00AM
Aug 30, 2023 07:00AM
Jul 17, 2023 07:00AM BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investi
May 24, 2023 07:00AM
May 17, 2023 07:00AM
Apr 25, 2023 07:01AM
Apr 25, 2023 07:00AM
Apr 17, 2023 11:01AM
Apr 17, 2023 11:00AM
Mar 22, 2023 07:00AM BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates
Mar 15, 2023 07:00AM
Mar 6, 2023 07:00AM
Feb 8, 2023 09:00PM
Feb 3, 2023 09:00PM
Jan 29, 2023 09:00PM
Jan 23, 2023 09:00PM
Jan 4, 2023 07:00AM BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
Dec 20, 2022 07:01AM
Dec 20, 2022 07:00AM
Nov 28, 2022 04:30PM
Nov 15, 2022 07:00AM
Nov 10, 2022 04:30PM
Nov 10, 2022 07:02AM
Nov 10, 2022 07:01AM BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization
Nov 4, 2022 04:31PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All